Complications persist after phaco in eyes with pseudoexfoliation and nonsutured CTR implantation
Click Here to Manage Email Alerts
LAS VEGAS — Nonsutured capsular tension ring implantation after phacoemulsification did not prevent capsular or IOL complications in eyes with pseudoexfoliation, according to a study presented here.
“Sadly, there is very scarce literature on the postoperative outcomes [of capsular tension rings (CTRs)],” Yan-Ning Neo, MBCHB, said at the American Academy of Ophthalmology annual meeting. “Therefore, we question whether nonsutured CTR implantations prevent postoperative complications in pseudoexfoliation eyes with zonular weakness that underwent phacoemulsification with IOL implantation.”
Of 318 eyes with pseudoexfoliation included in the prospective study, 53 had zonular weakness and CTR implantation (group A), 117 had zonular weakness but did not have CTR implantation (group B), and 148 were in the control group with no zonular weakness or CTR implantation (group C).
When incidences of postoperative complications were stratified by severity, 17 patients in group A, 28 patients in group B and 9 patients in group C had either pseudophakodonesis, capsular contraction/phimosis or IOL decentration/dislocation. There was no statistically significant difference between groups A and B, demonstrating that there is a relationship between zonular weakness and risk of postoperative complication, independent of pseudoexfoliation, Neo said.
There was no statistically significant difference in postoperative visual acuity, IOP or glaucoma medication requirements between all three groups.
“In the absence of signs of zonular weakness, any pseudoexfoliation eyes should still be addressed with caution as it relates to zonular issues that may complicate any postoperative recovery,” Neo said. — by Kristie L. Kahl
Reference:
Neo YN. Postoperative outcome of capsular tension ring implantation in eyes with pseudoexfoliation. Presented at: American Academy of Ophthalmology annual meeting. Nov. 15, 2015; Las Vegas.
Disclosure: Neo reports no relevant financial disclosures.